Ovation Science Inc - President and CEO, Terry Howlett
President and CEO, Terry Howlett
Source: Las Vegas Sun
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Ovation Science Inc. (OVAT) has developed new high-dose CBD formulations for both its beauty, and its health and wellness lines
  • Ovation is a cannabis research and development company and has over twenty-five topical formulations developed including THC, CBD, combinations of the two, but wants to expand the dosage range of its CBD formulations
  • It has now developed a CBD transdermal cream formulation with 1500 milligrams of CBD per 30 millilitres to give a consumer a 3000-milligram jar of transdermal CBD cream
  • CBD derived from hemp, is expected to grow at a compound annual growth rate of 21.2 per cent from 2021 to 2028 owing to increasing demand and rising awareness
  • Ovation’s products have advantages over cannabis products that are smoked or ingested including avoiding the side-effects from smoking and eliminating the first pass effect through the liver
  • Ovation Science Inc. (OVAT) is unchanged trading at $0.085 per share as of 12:07 p.m. EST

Ovation Science (OVAT) has developed new high-dose CBD formulations for both its beauty, and health and wellness lines.

The company has introduced a CBD transdermal cream formulation with 1500 milligrams of CBD per 30 millilitres to give a consumer a 3000-milligram jar of transdermal CBD cream.

Ovation is a cannabis research and development company and has over twenty-five topical formulations developed including THC, CBD, combinations of the two, but wants to expand the dosage range of its CBD formulations.

Terry Howlett, CEO of Ovation Science stated,

“We believe there is a demand for high dose CBD topicals and transdermal creams and we are excited to explore these new opportunities further with potential licensees.”

According to a ResearchAndMarkets.com report, CBD derived from hemp is expected to grow at a compound annual growth rate of 21.2 per cent from 2021 to 2028 owing to increasing demand and raising awareness.

Ovation’s licensee for Nevada sells its Invisicare® powered CBD and CBD/THC combo formulations to dispensaries across Nevada.

Ovation noted that these topical product formulations rank in the top five in sales in Nevada dispensaries.

Ovation is prepared to duplicate this success and is seeking licensees in the other 36 approved states to implement this plan.

Ovation management has over twenty years of topical drug delivery experience and has leveraged this experience and technology to develop a series of topical and transdermal cannabis products.

Ovation’s products have advantages over cannabis products that are smoked or ingested including avoiding the side-effects from smoking and eliminating the first-pass effect through the liver.

Ovation Science Inc. (OVAT) is unchanged trading at $0.085 per share as of 12:07 p.m. EST.

More From The Market Herald

" BioHarvest (CSE:BHSC) predicts 2022 revenue to grow up to 3.5 times

BioHarvest Sciences Inc. (BHSC) expects strong revenue growth to continue in 2022 due to a successful over-delivery of projected revenue targets from last year.

" Icanic Brands (CSE:ICAN) agrees to acquire cannabis extraction company

Icanic Brands Company (ICAN) has signed a definitive agreement to acquire 100 per cent of LEEF Holdings Inc.
Tilray - Denise Faltischek, Head of International and Chief Strategy Officer.

" Tilray (TSX:TLRY) expands Australian medical cannabis offering

Tilray (TLRY) has expanded its medical cannabis product suite in Australia.

" Craftport Cannabis (CSE:CFT) announces $3M private placement

Craftport Cannabis (CFT) has announced a non-brokered private placement for gross proceeds of $3 million.